Patent US4680289A successfully refreshed from Google Patents.
US4680289A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of obesity and diabetes using sapogenins
Assignee: Astex Pharmaceuticals Inc
•
Filing: 1985-06-05
•
Granted: 1987-07-14
•
Expires: 2005-06-05
Abstract
Abstract Obesity and diabetes obesity syndromes are treated with 5β-sapogenin or Δ 5 sapogenin.
Inventors
- 👤 Norman Applezweig
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 13:55
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/58; A61P; A61P3/00; A61P3/04; A61P3/08; A61P3/10
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
37 words
A method of treating a condition selected from the group consisting of obesity and diabetes syndromes which comprises administering to a mammal an obesity or diabetes antagonizing effectuve amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 2
Independent Claim
37 words
A method of treating a condition selected from the group consisting of obesity and diabetes syndromes which comprises administering to a mammal an obesity or diabetes antagonizing effectuve amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein the administration is oral or parental.
Claim 4
Dependent Claim
10 words
The method of claim 2, wherein said sapogenin is diosgenin.
Claim 5
Dependent Claim
12 words
The method of claim 2, wherein said sapogenin is smilagenin or sarsasapogenin.
Claim 6
Dependent Claim
16 words
The method of claim 1, wherein the amount administered is about 25-2,000 mg. per 70 kilos.
Claim 7
Dependent Claim
12 words
The method of claim 5, wherein the amount is about 100-800 mg.
Claim 8
Dependent Claim
14 words
The method of claim 1, wherein said sapogenin is administered in combination with food.
Claim 9
Dependent Claim
20 words
The method of claim 7, wherein said sapogenin is present in an amount up to about 1% of said food.
Claim 10
Dependent Claim
14 words
The method of claim 7, wherein said sapogenin is in finely dispersed powdered form.
Claim 11
Dependent Claim
14 words
The method of claim 1, wherein said sapogenin is in finely dispersed powdered form.
Claim 12
Independent Claim
23 words
A method of treating obesity comprising administering to a mammal an obesity antagonizing effective amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 13
Independent Claim
23 words
A method of treating obesity comprising administering to a mammal an obesity antagonizing effective amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 14
Dependent Claim
10 words
The method of claim 11, wherein said sapogenin is diosgenin.
Claim 15
Dependent Claim
12 words
The method of claim 11, wherein said sapogenin is smilagenin or sarsasapogenin.
Claim 16
Dependent Claim
16 words
The method of claim 11, wherein the amount administered is about 25-2,000 mg. per 70 kilos.
Claim 17
Dependent Claim
11 words
The method of claim 14, wherein the amount is 100-800 mg.
Claim 18
Dependent Claim
38 words
A composition for the treatment of a condition selected from the group consisting of obesity and diabetes syndromes comprising in combination, food and an obesity or diabetes antagonizing effective amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 19
Dependent Claim
38 words
A composition for the treatment of a condition selected from the group consisting of obesity and diabetes syndromes comprising in combination, food and an obesity or diabetes antagonizing effective amount of a 5β-sapogenin or a Δ 5 sapogenin.
Claim 20
Dependent Claim
10 words
The composition of claim 16, wherein said sapogenin is diosgenin.
Claim 21
Dependent Claim
12 words
The composition of claim 16, wherein said sapogenin is smilagenin or sarsasapogenin.
Claim 22
Dependent Claim
20 words
The composition of claim 16, wherein said sapogenin is present in an amount up to about 1% of said food.
Claim 23
Independent Claim
23 words
A method of treating diabetes syndromes which comprises administering to a mammal a diabetes antagonizing effective amount of 5β-sapogenin or Δ 5 sapogenin.
Claim 24
Independent Claim
23 words
A method of treating diabetes syndromes which comprises administering to a mammal a diabetes antagonizing effective amount of 5β-sapogenin or Δ 5 sapogenin.
Claim 25
Dependent Claim
10 words
The method of claim 20, wherein said sapogenin is diosgenin.
Claim 26
Dependent Claim
12 words
The method of claim 20, wherein said sapogenin is smilagenin or sarsasapogenin.
Claim 27
Dependent Claim
16 words
The method of claim 20, wherein the amount administered is about 25-2,000 mg. per 70 kilos.
Claim 28
Dependent Claim
11 words
The method of claim 23, wherein the amount is 100-800 mg.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-13 | 1991-01-12 | 1991-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-13 | 1995-01-12 | 1995-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-13 | 1999-01-12 | 1999-07-14 | $7700.00 | Window Closed / Lapsed |